November 21st 2023
Your daily dose of the clinical news you may have missed.
November 17th 2023
November 14th 2023
November 13th 2023
TLM 2023: Speech analyzed from a smartphone app recording identified MHE and predicted OHE with results comparable to those from validated assessments.
TLM 2023: Reduce disease stigma and treatment inequality, build awareness for early diagnosis across specialties, support clinicians with accessible tools, and that's a start.
10 Top Studies from The Liver Meeting 2023: At-a-Glance
Simplified risk stratification tools for NAFLD, effects of statins on hepatic disease, trends in OHE, and patient perspectives are samples of the noteworthy research areas.
Underestimation of OHE Hospitalizations: Author of New Study Discusses Clinical Implications, Takeaways for Primary Care Clinicians
Arun Jesudian, MD, details key findings from a study he recently presented at The Liver Meeting 2023.
NASH Diagnosis: Patients Overwhelmed But Motivated to Adhere to Guidance and Want More Help, Survey Finds
More education that is clear and from reliable sources is needed for patients with a NASH diagnosis and their caregivers throughout the duration of the disease.
Cloud-Based "Liver Toolkit" Identifies Primary Care Patients at High Risk for Fibrosis, Requiring Referral
One in 5 patients identified as at risk for advanced chronic liver disease had advanced fibrosis and PCP was prompted to refer to hepatology.
FIB-4 Risk-Stratification Algorithm for MASLD Improved Primary Care Practice Patterns, According to New Research
TLM 2023: Primary care clinicians exposed to a FIB4-based risk stratification algorithm reported applying it routinely for patients with elevated LFTs after the introduction.
New Data Show Rise in Decompensated Cirrhosis and Hepatic Encephalopathy Cases among US Medicare Beneficiaries
TLM 2023: Over 15 years, decompensated cirrhosis and OHE notably rose among Medicare beneficiaries with cirrhosis, exceeding 40% and 20% in 2020.
New NAFLD Familial Risk Score Outperforms FIB-4 for Predicting Advanced Fibrosis in First-Degree Relatives
TLM 2023: The simple noninvasive tool may be an alternative to FIB-4, researchers said, and the new data may have implications for NAFLD surveillance.
Novel Algorithm, FAST-3, Shows Promise as Noninvasive Classifier for Advanced Fibrosis in MASLD
The predictive algorithm uses FibroScan-captured CAP and LSM data plus 5 clinical variables to identify advanced fibrosis in persons with MASLD.
Hepatic Steatosis is a Risk Factor for MACE, Even Among Individuals at Low 10-Year ASCVD Risk
TLM 2023: The burden of CAD is similar between persons with hepatic steatosis at low and high ASCVD risk, but rate of MACE is higher in the low-risk population.
Rifaximin Significantly Reduced Recurrent OHE and Associated Health Care Utilization
TLM 2023: Use of rifaximin significantly reduced mean number of OHE episodes as well as hospital contacts, including ED visits and admissions.
Statin Protection Against Cirrhosis in Adults with NAFLD More Pronounced with Age
TLM 2023: Investigators found that the protective effects of statin therapy against late stage liver disease increased with age older than 51 years.
New Research Reveals Underestimation of Overt Hepatic Encephalopathy Hospitalizations in US
TLM 2023: Relying solely on a primary diagnosis for overt hepatic encephalopathy underestimates the actual rate, length of stay, and costs of OHE hospitalizations.
STUDY: Novel “Triagonist” Retatrutide Resolved Steatosis in Over 85% of Patients with MASLD and Obesity
TLM 2023: In participants with metabolic dysfunction-associated steatotic liver disease, retatrutide 8 mg and 12 mg resolved steatosis in >85% of subjects.
Chronic Liver Disease Prevalence May Triple by Decade's End, New Report Projects
Driven largely by the widespread increase in diabetes and obesity, the rise in hepatic disease disparately affects minority populations and is outpacing available medical care.
It's High Time to Retire NAFLD: Multinational Liver Societies Explain
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.
NAFLD is Now MASLD: The New Nomenclature, At-a-Glance
The shift in naming for diseases historically known as nonalcoholic fatty liver disease will be top of mind at The Liver Meeting 2023. Get a quick look at why.
The Liver Meeting 2023: AASLD Offers "Journey Maps" to Focused Areas of Interest
We took The Liver Meeting's 11 journey maps to educational sessions and focused on 4 that will be of interest to primary care.
Daily Dose: Oral Menopausal Hormone Therapy Associated with Higher Risk of NAFLD
Oral vs Transdermal Hormone Therapy after Menopause Linked to Increased Risk of NAFLD
Among postmenopausal women taking hormones orally, the NAFLD prevalence increased from 25.3 to 29.4% while it decreased from 24 to 17.3% in those using the transdermal route.
Pegozafermin Receives Breakthrough Therapy Designation for Nonalcoholic Steatohepatitis
The US Food and Drug Administration granted BTD to pegozafermin for the treatment of patients with NASH.
FDA Accepts Resmetirom NDA, Grants Priority Review, and Sets PDUFA Date
Resmetirom, a once-daily oral, thyroid hormone receptor (THR)-β selective agonist, targets key underlying NASH pathophysiology in the liver.
Remdesivir Gets FDA “OK” for COVID-19 Treatment in Hepatic Disease Across Stages
The expanded labeling for the antiviral against COVID-19 indicates no dose adjustment is required for persons across all stages of liver disease.
Daily Dose: Daily Sugared Drink Intake & Risk of Hepatic Morbidity, Mortality in Postmenopausal Women
A daily dose of clinical news on Patient Care you may have missed.
Daily Sugared Drink Consumption May Increase Risk of Hepatic Morbidity, Mortality in Older Women
Postmenopausal women who consumed 1 or more sugary drinks daily had a nearly 2-fold increased risk of liver cancer in a study of more than 98 000.
Less than Half of Patients with New AF Diagnosis Prescribed Oral Anticoagulation within 6 Months
Factors positively associated with a timely first OAC Rx among the 41.3% who received one included male sex, certain comorbidities, other current medications, and obesity.
Daily Dose: T2D Raises Risk for Hepatic Decompensation, Hepatocellular Carcinoma in Patients with NAFLD
Your daily dose of clinical news you may have missed.
In Patients with NAFLD, Type 2 Diabetes Significantly Ups Risk for Hepatic Decompensation, Hepatocellular Carcinoma
In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .
Daily Dose: Pegozafermin in Patients with NASH
ADA Updates Standards of Care, Adding Teplizumab for Delay of T1D, Emphasizing Hepatic Disease Management
The ADA's annual update includes refined criteria for type 1 diabetes screening and detailed guidance on detection and management of NAFLD and NASH.
Pegozafermin Shows Early Promise in NASH: Phase 2b ENLIVEN Trial Findings
Pegozafermin, an investigational long-acting (FGF21) analogue, was associated with fibrosis improvement and NASH resolution in an average of 25% of study participants.
2 Clarke Drive Cranbury, NJ 08512